Showing results (91-100 of 112) with videos related to

Sort By:
Pageof 12
Cancer Immunology, Immunotherapy : CII|January 1, 1993
Immunization of breast cancer patients using a synthetic sialyl-Tn glycoconjugate plus Detox adjuvantG D MacLean, M Reddish, R R Koganty, et al.
Bioconjugate Chemistry|July 21, 1998
Liposomal formulations of synthetic MUC1 peptides: effects of encapsulation versus surface display of peptides on immune responsesH H Guan, W Budzynski, R R Koganty, et al.
Biochimica Et Biophysica Acta|May 9, 2001
Anti-MUC-1 immunoliposomal doxorubicin in the treatment of murine models of metastatic breast cancerE H Moase, W Qi, T Ishida, et al.
The International Journal of Biological Markers|January 1, 1991
Possible utility of serum determinations of CA 125 and CA 27.29 in breast cancer managementJ L Jensen, G D Maclean, M R Suresh, et al.
Cancer Immunology, Immunotherapy : CII|May 11, 1999
Vaccines prepared with sialyl-Tn and sialyl-Tn trimers using the 4-(4-maleimidomethyl)cyclohexane-1-carboxyl hydrazide linker group result in optimal antibody titers against ovine submaxillary mucin and sialyl-Tn-positive tumor cellsG Ragupathi, L Howard, S Cappello, et al.
Glycoconjugate Journal|October 1, 1995
Structurally defined synthetic cancer vaccines: analysis of structure, glycosylation and recognition of cancer associated mucin, MUC-1 derived peptidesX Liu, J Sejbal, G Kotovych, et al.
American Journal of Medical Genetics|October 1, 1992
Portohepatic shunt in a Down syndrome patient with an interchange trisomy 47,XY,-2,+der(2),+der(21)t(2;21)(p13;q22.1)matM W Kieran, M Vekemans, L J Robb, et al.
Glycoconjugate Journal|June 25, 2003
MUC1-specific CTLs are non-functional within a pancreatic tumor microenvironmentP Mukherjee, A R Ginardi, C S Madsen, et al.
Bone Marrow Transplantation|June 29, 2000
Clinical outcome of breast and ovarian cancer patients treated with high-dose chemotherapy, autologous stem cell rescue and THERATOPE STn-KLH cancer vaccineL A Holmberg, D V Oparin, T Gooley, et al.
Cancer Research|July 1, 1995
GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21F Helling, S Zhang, A Shang, et al.
Pageof 12